Antifibrotic Therapy for Chronic Kidney Disease

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$271,934.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK085841-01A1
Award Id:
96041
Agency Tracking Number:
DK085841
Solicitation Year:
n/a
Solicitation Topic Code:
NIDDK
Solicitation Number:
n/a
Small Business Information
ANGION BIOMEDICA CORP, 1050 Stewart Ave., GARDEN CITY, NY, 11530
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
053129065
Principal Investigator:
PRAKASHNARAYAN
(516) 326-1200
PNARAYAN@ANGION.COM
Business Contact:
ITXHAKGOLDBERG
() -
igoldberg@angion.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Chronic kidney disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. For decades, Abl, c-KIT, PDGFR, KDR, and EGFR receptor tyrosine kinases have been implicated in growth factor signaling and angiogenesis. They have therefore been the targets for successful molecular targeted anti-neoplastic therapeutics. However, there is a substantial body of evidence that certain receptor tyrosine kinases, including PDGFR and KDR can also be promising target s for anti-fibrotic agents. While anti-neoplastic therapeutics have successfully been developed for use in oncology, it remains unclear whether these small molecules are suitable for use as antifibrotic agents. Angion Biomedica has identified ANG3154, a sm all molecule with PDGFR and KDR inhibitory activity. In experimental models of pulmonary and renal fibrosis, orally administered ANG3154 has exhibited powerful antifibrotic effects. Based on these compelling preliminary data, the present SBIR Phase I propo sal is designed to make an in-depth analysis of the antifibrotic effects of ANG3154 in experimental CKD. PUBLIC HEALTH RELEVANCE: A small molecule orally bioactive antifibrotic has significant clinical potential for treatment of chronic kidney disea se.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government